Home › Burkitt Lymphoma › NCT07422337

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination

Who can join

Ages 1 to 23 · All sexes

Inclusion Criteria:

* Diagnosis of B-lineage acute lymphoblastic leukemia/lymphoma
* ≥1 year old and up to 21 years old at diagnosis
* Informed consent provided, and if applicable, child assent provided
* Must have received all vaccinations routinely administered during first year of life

Exclusion Criteria:

* Relapsed/refractory disease at any time
* Received or will require a bone marrow transplant and/or cellular therapy
* Pregnancy

About the study

The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are:

* Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL/Ly who have received blinatumomab. * To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity.

Researchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.

Sponsor: Arkansas Children's Hospital Research Institute · Participants: 300 · Started: Jan 13, 2026

Contact the study team

• Lauren Appell, MD · Phone: 501-364-1494
• Stephanie Thomas, RN · Phone: 501-364-3820

Official record on ClinicalTrials.gov — NCT07422337

Locations in the U.S.

Conditions

• Burkitt Lymphoma
• Lymphoma
• B-Cell Leukemia
• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.